- Previous Close
0.0900 - Open
0.1000 - Bid 0.0900 x --
- Ask 0.1000 x --
- Day's Range
0.1000 - 0.1000 - 52 Week Range
0.0350 - 0.1100 - Volume
65,000 - Avg. Volume
167,580 - Market Cap (intraday)
16.712M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Nov 27, 2024 - Dec 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
hemostemix.com--
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: HEM.V
View More
Performance Overview: HEM.V
Trailing total returns as of 2024-11-01, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEM.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEM.V
View MoreValuation Measures
Market Cap
15.04M
Enterprise Value
19.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-349.24%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.94M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
103.75k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-212.5k